Matever 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
amended 
on 
IB/0043/G 
This was an application for a group of variations. 
27/06/2023 
SmPC and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0042 
C.I.2.a - Change in the SPC, Labelling or PL of a 
09/06/2022 
18/11/2022 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0041/G 
This was an application for a group of variations. 
29/11/2021 
18/11/2022 
Annex II and 
PL 
B.II.b.1.e - Replacement or addition of a 
manufacturing site for the FP - Site where any 
manufacturing operation(s) take place, except batch-
release, batch control, primary and secondary 
packaging, for non-sterile medicinal products 
B.II.b.2.c.2 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Including batch control/testing 
B.II.b.4.a - Change in the batch size (including batch 
size ranges) of the finished product - Up to 10-fold 
compared to the originally approved batch size 
B.II.b.5.b - Change to in-process tests or limits 
applied during the manufacture of the finished 
Page 2/11 
 
 
 
 
 
 
 
 
 
 
product - Addition of a new test(s) and limits 
N/0040 
Minor change in labelling or package leaflet not 
29/09/2021 
18/11/2022 
PL 
connected with the SPC (Art. 61.3 Notification) 
IAIN/0039 
B.II.a.3.a.1 - Changes in the composition 
06/08/2021 
n/a 
(excipients) of the finished product - Changes in 
components of the flavouring or colouring system - 
Addition , deletion or replacement 
IB/0038 
C.I.2.a - Change in the SPC, Labelling or PL of a 
01/06/2021 
17/06/2021 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0037/G 
This was an application for a group of variations. 
13/01/2021 
17/06/2021 
SmPC and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Page 3/11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IA/0036/G 
This was an application for a group of variations. 
09/12/2020 
n/a 
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
N/0035 
Minor change in labelling or package leaflet not 
24/06/2020 
24/09/2020 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0034 
C.I.2.a - Change in the SPC, Labelling or PL of a 
30/03/2020 
24/09/2020 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
Page 4/11 
 
 
 
 
 
 
 
 
 
 
 
 
 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0033 
C.I.2.a - Change in the SPC, Labelling or PL of a 
04/10/2019 
24/09/2020 
SmPC, Annex 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
II, Labelling 
and PL 
II/0032 
B.II.e.1.b.2 - Change in immediate packaging of the 
14/06/2019 
n/a 
finished product - Change in type/addition of a new 
container - Sterile medicinal products and 
biological/immunological medicinal products 
IB/0031/G 
This was an application for a group of variations. 
24/10/2018 
21/10/2019 
SmPC, 
Labelling and 
PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
Page 5/11 
 
 
 
 
 
 
 
 
 
 
 
 
 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
N/0030 
Minor change in labelling or package leaflet not 
02/07/2018 
21/10/2019 
PL 
connected with the SPC (Art. 61.3 Notification) 
N/0029 
Minor change in labelling or package leaflet not 
31/05/2017 
25/01/2018 
PL 
connected with the SPC (Art. 61.3 Notification) 
N/0028 
Minor change in labelling or package leaflet not 
30/03/2017 
25/01/2018 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0027 
C.I.2.a - Change in the SPC, Labelling or PL of a 
16/01/2017 
25/01/2018 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0026 
B.II.b.4.a - Change in the batch size (including batch 
05/12/2016 
n/a 
size ranges) of the finished product - Up to 10-fold 
compared to the originally approved batch size 
IAIN/0025 
B.III.1.a.3 - Submission of a new/updated or 
10/10/2016 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from a 
new manufacturer (replacement or addition) 
Page 6/11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N/0024 
Update of the package leaflet with revised contact 
07/07/2016 
25/01/2018 
PL 
details of the local representatives for Lithuania, 
Estonia and Latvia, for the film-coated tablets 
presentations (EU/1/11/711/001-029). 
Minor change in labelling or package leaflet not 
connected with the SPC (Art. 61.3 Notification) 
R/0023 
Renewal of the marketing authorisation. 
28/04/2016 
29/06/2016 
SmPC, Annex 
Based on the review of data on quality, safety and efficacy, 
II, Labelling 
the CHMP considered that the benefit-risk balance of 
and PL 
Matever in the approved indications remains favourable and 
therefore recommended the renewal of the marketing 
authorisation with unlimited validity. 
IAIN/0022 
B.III.1.a.1 - Submission of a new/updated or 
13/01/2016 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from 
an already approved manufacturer 
IAIN/0021 
C.I.8.a - Introduction of or changes to a summary of 
12/05/2015 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
II/0018 
B.II.d.1.e - Change in the specification parameters 
26/03/2015 
n/a 
and/or limits of the finished product - Change 
outside the approved specifications limits range 
N/0020 
Minor change in labelling or package leaflet not 
26/02/2015 
29/06/2016 
PL 
connected with the SPC (Art. 61.3 Notification) 
Page 7/11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0019/G 
This was an application for a group of variations. 
12/01/2015 
n/a 
B.II.b.1.f - Replacement or addition of a 
manufacturing site for part or all of the 
manufacturing process of the FP - Site where any 
manufacturing operation(s) take place, except batch 
release, batch control, and secondary packaging, for 
sterile medicinal products (including those that are 
aseptically manufactured) excluding biological/ 
immunological medicinal products 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.b.4.a - Change in the batch size (including batch 
size ranges) of the finished product - Up to 10-fold 
compared to the originally approved batch size 
N/0017 
Minor change in labelling or package leaflet not 
02/10/2014 
15/01/2015 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0016/G 
This was an application for a group of variations. 
05/05/2014 
15/01/2015 
SmPC, Annex 
II and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
Page 8/11 
 
 
 
 
 
 
 
 
 
 
 
 
 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
N/0015 
Minor change in labelling or package leaflet not 
01/04/2014 
15/01/2015 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0013 
C.I.2.a - Change in the SPC, Labelling or PL of a 
19/12/2013 
15/01/2015 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IAIN/0011 
C.I.8.a - Introduction of or changes to a summary of 
21/10/2013 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
N/0010 
Minor change in labelling or package leaflet not 
28/08/2013 
15/01/2015 
PL 
connected with the SPC (Art. 61.3 Notification) 
N/0009 
Minor change in labelling or package leaflet not 
21/05/2013 
15/01/2015 
PL 
connected with the SPC (Art. 61.3 Notification) 
N/0008 
Minor change in labelling or package leaflet not 
06/02/2013 
15/01/2015 
PL 
connected with the SPC (Art. 61.3 Notification) 
Page 9/11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0006 
C.I.2.a - Change in the SPC, Labelling or PL of a 
24/08/2012 
28/09/2012 
SmPC, 
Section 4.8 of the SmPC was updated in order to add ‘panic 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
Labelling and 
attack’ as an undesirable effect following the cumulative 
PL 
review of the safety data for Keppra (II-131). The Package 
Leaflet was updated in accordance. In addition, editorial 
changes were made to sections 2 and 4.1 of the SmPC. 
Section 2 of the Package Leaflet was updated in order to 
change the description of the quantity of the sodium 
excipient in Matever concentrate for solution for infusion. 
Moreover, the description of pancytopenia, erythema 
multiforme, Stevens-Johnsons syndrome and toxic 
epidermal necrolysis in section 4 of the package Leaflet was 
updated. The PI was brought in line with the latest QRD 
template, version 8 and details for local representatives in 
IT and NL were updated in Annex III B. 
N/0004 
Minor change in labelling or package leaflet not 
22/05/2012 
28/09/2012 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0003 
C.I.2.a - Change in the SPC, Labelling or PL of a 
04/04/2012 
28/09/2012 
SmPC and PL 
This variation is to update section 4.8 of the SmPC and 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
IAIN/0002 
C.I.9.i - Changes to an existing pharmacovigilance 
06/01/2012 
n/a 
system as described in the DDPS - Change(s) to a 
DDPS following the assessment of the same DDPS in 
section 4 of the PIL as a consequence of the adoption by 
the CHMP of safety variations related to significant 
modifications of the Summary of Product Characteristics 
(SmPC) due in particular to new quality, pre-clinical, clinical 
or pharmacovigilance data to Matever's reference medicinal 
product Keppra.  
Additional minor editorial changes were made to the 
Portuguese and Slovakian SmPCs. 
Page 10/11 
 
 
 
 
 
 
 
 
 
 
 
 
relation to another medicinal product of the same 
MAH 
N/0001 
The Marketing Authorisation Holder (MAH) took the 
22/11/2011 
28/09/2012 
PL 
opportunity to update details of local representatives 
in Annex IIIB. 
Minor change in labelling or package leaflet not 
connected with the SPC (Art. 61.3 Notification) 
Page 11/11 
 
 
 
 
 
 
 
 
 
 
